GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » EQL Pharma AB (FRA:7JK) » Definitions » Cyclically Adjusted Revenue per Share

EQL Pharma AB (FRA:7JK) Cyclically Adjusted Revenue per Share : €0.46 (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is EQL Pharma AB Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

EQL Pharma AB's adjusted revenue per share for the three months ended in Jun. 2024 was €0.252. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.46 for the trailing ten years ended in Jun. 2024.

During the past 12 months, EQL Pharma AB's average Cyclically Adjusted Revenue Growth Rate was 19.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-09-25), EQL Pharma AB's current stock price is €4.65. EQL Pharma AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2024 was €0.46. EQL Pharma AB's Cyclically Adjusted PS Ratio of today is 10.11.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of EQL Pharma AB was 10.31. The lowest was 5.25. And the median was 7.16.


EQL Pharma AB Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for EQL Pharma AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EQL Pharma AB Cyclically Adjusted Revenue per Share Chart

EQL Pharma AB Annual Data
Trend Dec14 Dec15 Dec16 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.41 0.44

EQL Pharma AB Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.40 0.39 0.43 0.44 0.46

Competitive Comparison of EQL Pharma AB's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, EQL Pharma AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EQL Pharma AB's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, EQL Pharma AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where EQL Pharma AB's Cyclically Adjusted PS Ratio falls into.



EQL Pharma AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, EQL Pharma AB's adjusted Revenue per Share data for the three months ended in Jun. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=0.252/132.7160*132.7160
=0.252

Current CPI (Jun. 2024) = 132.7160.

EQL Pharma AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.036 100.432 0.048
201409 0.027 100.161 0.036
201412 0.020 100.225 0.026
201503 0.040 99.950 0.053
201506 0.039 99.995 0.052
201509 0.031 100.228 0.041
201512 0.028 100.276 0.037
201603 0.057 100.751 0.075
201606 0.019 101.019 0.025
201609 0.013 101.138 0.017
201612 0.031 102.022 0.040
201703 0.021 102.022 0.027
201706 0.037 102.752 0.048
201709 0.033 103.279 0.042
201803 0.000 103.962 0.000
201806 0.039 104.875 0.049
201809 0.052 105.679 0.065
201812 0.037 105.912 0.046
201903 0.047 105.886 0.059
201906 0.047 106.742 0.058
201909 0.063 107.214 0.078
201912 0.068 107.766 0.084
202003 0.059 106.563 0.073
202006 0.327 107.498 0.404
202009 0.080 107.635 0.099
202012 0.094 108.296 0.115
202103 0.087 108.360 0.107
202106 0.127 108.928 0.155
202109 0.178 110.338 0.214
202112 0.393 112.486 0.464
202203 0.621 114.825 0.718
202206 0.147 118.384 0.165
202209 0.230 122.296 0.250
202212 0.244 126.365 0.256
202303 0.182 127.042 0.190
202306 0.163 129.407 0.167
202309 0.169 130.224 0.172
202312 0.212 131.912 0.213
202403 0.232 132.205 0.233
202406 0.252 132.716 0.252

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


EQL Pharma AB  (FRA:7JK) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

EQL Pharma AB's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=4.65/0.46
=10.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of EQL Pharma AB was 10.31. The lowest was 5.25. And the median was 7.16.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


EQL Pharma AB Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of EQL Pharma AB's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


EQL Pharma AB Business Description

Industry
Traded in Other Exchanges
Address
Stortorget 1, 3rd Floor, Lund, SWE, 222 23
EQL Pharma AB is a pharmaceutical company engaged in developing and selling medicines to pharmacies and hospitals. The products offered by the company include generics and parallel imports. It operates and markets products to Nordic countries of Sweden, Denmark, Finland and Norway.

EQL Pharma AB Headlines

No Headlines